This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

IQ HUB

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Overview

descGeneral Itemother|keytruda-heritagepublicationdatetypeofcontent|otherdate02350tcm:4244-1243064KEYTRUDA® (pembrolizumab) Dosing and Administration/static/mciuk/images/msdc_keytruda_dosing_and_admin_guide_monotherapy.pngKEYTRUDA® (pembrolizumab) Dosing and Administration/static/mciuk/pdf/KEYTRUDA_Dosing_and_administration_guide_for_monotherapy.pdf <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]branded/static/mciuk/images/msdc_keytruda_dosing_and_admin_guide_monotherapy.pngpublishDateTime2021-10-18T09:50:51assetIdtcm:4244-1243064pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-03-24codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1241138KEYTRUDA® (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]crc-mono/static/mciuk/images/keytruda_moa@2x.pngpublishDateTime2021-11-02T11:38:54assetIdtcm:4244-1241138pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordscrc-monospecialityexpirationdatehotpublicationdate2020-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionThis page contains video information on the mode of action for KEYTRUDA▼ (pembrolizumab) and is intended only for UK Healthcare Professionals.asset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1039566KEYTRUDA® (pembrolizumab) in combination with chemotherapy: proposed mode of action video/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.pngKEYTRUDA® (pembrolizumab) in combination with chemotherapy: proposed mode of action video/training-resources/keytruda/keytruda-in-combination-moa.xhtml <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]branded/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.pngpublishDateTime2021-10-18T09:44:49assetIdtcm:4244-1039566pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2019-03-03codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00

Rating

KEYTRUDA® (pembrolizumab) Dosing and Administration

Prescribing Information (Great Britain)Prescribing Information (Northern Ireland)[External links]

Rating

KEYTRUDA® (pembrolizumab) Mode of Action

Prescribing Information (Great Britain)Prescribing Information (Northern Ireland)[External links]

Rating

KEYTRUDA® (pembrolizumab) in combination with chemotherapy: proposed mode of action video

Prescribing Information (Great Britain)Prescribing Information (Northern Ireland)[External links]

< Previous 1 Next >

Adverse Event management and identification

Rating

A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-related adverse events

Prescribing Information (Great Britain)Prescribing Information (Northern Ireland)[External links]

< Previous 1 Next >

Patient assets

descGeneral Itemother|keytruda-patient-assetpublicationdatetypeofcontent|otherdate01250tcm:4244-1285147Take a closer look at your untreated PD-L1 ≥50% TPS mNSCLC patients/static/mciuk/images/take-a-closer-look-at-your-untreated-mnsclc-patients-thumbnail.pngTake a closer look at your untreated PD-L1 ≥50% TPS mNSCLC patients/training-resources/keytruda/nsclc/untreated-pdl1-greater-50.xhtml <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]nsclc-mono/static/mciuk/images/take-a-closer-look-at-your-untreated-mnsclc-patients-thumbnail.pngpublishDateTime2022-05-13T12:34:29assetIdtcm:4244-1285147pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-11-04codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeOffsite LinkassetfranchiseOncologyasset_descriptionasset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1307557KEYTRUDA® (pembrolizumab) Monotherapy Patient Diary/static/mciuk/images/msdc_keytruda_pan_tumor_diary.png/training-resources/keytruda/mono-patient-diary.xhtml <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]branded/static/mciuk/images/msdc_keytruda_pan_tumor_diary.pngpublishDateTime2022-05-13T12:33:29assetIdtcm:4244-1307557pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-07-13codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeOffsite LinkassetfranchiseOncologyasset_descriptionasset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00